about
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1Methylation alterations are not a major cause of PTTG1 misregulation.Differential expression of THOC1 and ALY mRNP biogenesis/export factors in human cancers.The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth.Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.Prognostic value of CtIP/RBBP8 expression in breast cancer.Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.PTPL1 and PKCδ contribute to proapoptotic signalling in prostate cancer cells.Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors.Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type.Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancerInduction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation.Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancerNeuroblastoma initially presenting as a primary bone tumor: diagnostic value of molecular assays for tyrosine hydroxylase.Bone involvement and abcess formation by neutrophil-rich CD30+ anaplastic large-cell lymphoma mimicking skeletal infection in an AIDS patient.Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection.Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.Prognostic relevance of Src activation in stage II-III colon cancer.Mucinous (colloid) adenocarcinomas secrete distinct O-acylated forms of sialomucins: a histochemical study of gastric, colorectal and breast adenocarcinomas.G1/S phase progression is regulated by PLK1 degradation through the CDK1/βTrCP axis.Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer CellsA single mutation in Securin induces chromosomal instability and enhances cell invasionDownregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cellsImmunohistochemical Expression of Hsp60 Correlates With Tumor Progression and Hormone Resistance in Prostate CancerClinicopathological correlations of Bcl-xL and Bax expression in differentiated thyroid carcinomaPrognostic Significance of Human Pituitary Tumor-Transforming Gene Immunohistochemical Expression in Differentiated Thyroid CancerExpression of hpttg proto-oncogene in lymphoid neoplasiasStructural normalization of the lymphoid tissue in asymptomatic HIV-infected patients after 48 weeks of potent antiretroviral therapyLoss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancerp53 and FBXW7: Sometimes Two Guardians Are Worse than One
P50
Q28304512-BBA3D4F7-CDAA-4195-999B-A621BB6E585BQ33329701-1E5D3E71-E703-4883-B569-0ECDFF353FB9Q33823134-F095159A-5BA6-45CB-B138-677A9E89E9BCQ35752727-F39D9522-C335-48CA-A3B9-A4F75B413ECEQ37293102-A2F8A16D-0F9B-4CA7-AED2-FD627B1953E5Q37362851-D0A5AB27-2917-46FC-9A36-4BA5EC47E2C6Q37481139-77B96C8B-C277-484F-A860-2D69F4EF6E0EQ37687113-A4E03B8C-FBF6-42A4-9AD0-F779CFC5F6B2Q37706888-790A77C3-5905-46FD-889D-BC776080AADFQ38769948-AC9E187F-EE0A-46AE-93CF-CC6163D6AEF2Q38966217-0077A0B8-F8AE-44A3-B09F-A52A1749D473Q39170959-8AE14D24-9DFC-4454-BF2A-E019280DB17FQ39444559-7542FDC9-0E97-4482-8B2D-95FD760F4076Q39452029-E4A59C90-BB09-4CFF-9CB4-0CE97B0263D2Q40263616-97999417-6DC6-43A0-914B-8B8AEFF369AEQ41460325-CA42BC66-0729-4593-BACC-727CF175C585Q41564995-400CE641-6A9B-4C00-ABA2-EAAD273A5036Q41837765-351C5AE1-6C86-4809-9696-92962011B5DFQ42274998-EC1DDB70-B4D9-4062-B04E-F3AD14F29A4BQ44272414-A0309CCF-8709-4006-B022-F90961ED14A5Q44774718-3256772E-C6D8-4E19-94AE-3E2B90AE5333Q45423509-E2700383-D13B-4FF4-BCCB-41A473CAC8D9Q46727061-1D795BE9-75FE-4FAF-9BBE-4D6AAE9AB619Q48105525-DFE93C40-6678-4E40-8218-822D21338912Q49569330-79B5AF55-4505-4E2B-AE58-2C4F77B500EDQ50205274-F0F619D6-5378-43F8-8EEB-D2F5704BFF17Q50501016-CE817D08-F622-4D11-95E6-3205709E2491Q50762663-62E70D19-0553-46B6-8D70-8AEA2C2CBE5CQ60914605-3CFB21F6-3BDC-4583-B853-3142F8F00768Q61700538-E5DC9716-30B0-4568-AADE-770BE265836BQ61700541-1B690A38-386F-4FA3-89B2-CD6BD7BD8983Q61700546-ECAEDC00-2393-487E-B609-C7CCD026DC01Q61700550-7B38823E-299A-4CC2-9EA7-5D0962212A65Q61700552-75B2D406-5196-4D81-B231-42745DBA69CAQ61700558-65D3B88E-1D31-40AC-9701-A56913019451Q61700562-1128A5BC-FD0B-4B44-AB7D-B3EDB020D571Q63982498-D06B2C37-FD9C-423E-BB46-782B2A0AE251Q92121261-58FE2604-8243-4931-AFDC-BC0B06E99CF3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmen Sáez
@ast
Carmen Sáez
@en
Carmen Sáez
@es
Carmen Sáez
@nl
Carmen Sáez
@sl
type
label
Carmen Sáez
@ast
Carmen Sáez
@en
Carmen Sáez
@es
Carmen Sáez
@nl
Carmen Sáez
@sl
prefLabel
Carmen Sáez
@ast
Carmen Sáez
@en
Carmen Sáez
@es
Carmen Sáez
@nl
Carmen Sáez
@sl
P1053
B-9468-2015
P106
P21
P31
P3829
P496
0000-0002-8600-0508